Treatment plans and AD
The top six therapies for AD patients were topical glucocorticoids
(32.26%), oral antihistamines (28.66%), moisturizers (19.58%),
topical calcineurin inhibitors (TCI) (5.99%), glycyrrhizin (5.82%),
and dupilumab (5.8%) (Table 5). There was a significantly higher
proportion of severe AD patients who used moisturizer, topical
glucocorticoids, TCI, antibiotic ointments, oral antihistamines, oral
antibiotics, systemic glucocorticoids, cyclosporine, methotrexate,
tripterygium glycosides, glycyrrhizin, thalidomide, NB-UVB phototherapy,
dupilumab, gabapentin, antidepressants, and opioids than that of mild
and moderate AD patients. Common recommended therapies including TCI
(5.99%), dupilumab (5.8%), systematic glucocorticoids (4.05%),
cyclosporine (0.82%), methotrexate (0.54%), and NB-UVB (0.76%) have
low usage rates in the included population (Table 5).